The epigenetic silencing drug for chronic hepatitis B (HBV) is built on Tune’s TEMPO epigenetic editing platform, which is delivered to cells in lipid nanoparticles. Rather than irreversibly ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years. Tune is using a ...

Hepatitis C virus (HCV ... Finally, innovative vaccine candidates, such as nanoparticle-based vaccines displaying permuted E1E2 glycoproteins, have shown promise in eliciting robust neutralizing ...

In summary, in the following section, the effects of nanoparticles, using CS, HA, PEG, and PLGA as examples, on hepatitis, liver fibrosis, and liver cancer will be reviewed in detail. Hopefully, this ...

They are also not suitable for people who have hepatitis B co-infection (who should take a drug ... lamivudine and dolutegravir (also known as TLD), using nanoparticle technology. This could offer a ...

In 2020, Biocon disclosed the creation of an advanced oral hepatitis B drug formulation, offering enhanced effectiveness and convenience compared to traditional injectable options. Employing ...

The funding will accelerate the development of the company’s existing pipeline, currently anchored by Tune-401 – its clinical-stage epigenetic silencing drug for chronic Hepatitis B (HBV). It will ...

The funding will accelerate Tune’s product development, anchored by Tune-401 – a clinical-stage epigenetic silencing drug for chronic hepatitis B (HBV), a viral ... Tune-401 uses lipid nanoparticles ...

To counteract these challenges, novel strategies aim to restore the cancer immunity cycle. One approach involves directly injecting unadjuvanted influenza vaccines or drug-loaded oncolytic viruses ...

The phase 1 trial is testing the safety tolerability, pharmacokinetics, and pharmacodynamics of PVT201 in healthy volunteers and patients.